Edwards Lifesciences (EW) Faces FTC Penalty, Is The Stock Still Cheap?

Simply Wall St.07-18 23:25

AdvertisementRegulatory shock puts Edwards Lifesciences stock under a sharper lens The Federal Trade Commission’s record $12 million penalty tied to Edwards Lifesciences (EW) acquisition of JC Medical...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2652489232?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/411220-main-header/1756234467355","is_english":true,"pubTime":"2026-07-18 23:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652489232","market":"us","top_or_hot":-1,"title":"Edwards Lifesciences (EW) Faces FTC Penalty, Is The Stock Still Cheap?","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementRegulatory shock puts Edwards Lifesciences stock under a sharper lens The Federal Trade Commission’s record $12 million penalty tied to Edwards Lifesciences (EW) acquisition of JC Medical...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-ew/edwards-lifesciences/news/edwards-lifesciences-ew-faces-ftc-penalty-is-the-stock-still\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Edwards Lifesciences (EW) Faces FTC Penalty, Is The Stock Still Cheap?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEdwards Lifesciences (EW) Faces FTC Penalty, Is The Stock Still Cheap?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-18 23:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-ew/edwards-lifesciences/news/edwards-lifesciences-ew-faces-ftc-penalty-is-the-stock-still><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementRegulatory shock puts Edwards Lifesciences stock under a sharper lens The Federal Trade Commission’s record $12 million penalty tied to Edwards Lifesciences (EW) acquisition of JC Medical...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-ew/edwards-lifesciences/news/edwards-lifesciences-ew-faces-ftc-penalty-is-the-stock-still\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BFXG0V08.USD","symbol_name":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-ew/edwards-lifesciences/news/edwards-lifesciences-ew-faces-ftc-penalty-is-the-stock-still","article_id":"2652489232","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/411220-main-header/1756234467355"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-ew/edwards-lifesciences/news/edwards-lifesciences-ew-faces-ftc-penalty-is-the-stock-still","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2652489232","pubTimestamp":1784388308,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Regulatory shock puts Edwards Lifesciences stock under a sharper lens\nThe Federal Trade Commission’s record $12 million penalty tied to Edwards Lifesciences (EW) acquisition of JC Medical, along with new restrictions on future TAVR AR deals, has pushed the stock’s regulatory risk profile into sharper focus.\nSee our latest analysis for Edwards Lifesciences.\nSince the FTC action, Edwards Lifesciences’ recent 1 day share price return of 2.4% and 7 day return of 7.03% show selling pressure...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","LU0345774391.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) ACC","FTC":"First Trust Large Cap Growth Opp","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE00BYQQ9H92.USD":"BNY MELLON GLOBAL LEADERS \"A\" (USD) ACC","AGNG":"Global X Aging Population ETF","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","BK4082":"医疗保健设备","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BMED":"iShares Health Innovation Active ETF","EW":"爱德华兹","BK4504":"桥水持仓","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","BK4588":"碎股","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC","IHI":"iShares Dow Jones U.S. Medical D"},"translate_title":"Edwards Lifesciences (EW) 面临 FTC 处罚，股票还便宜吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMED":0.6,"AGNG":0.6,"IHI":0.6,"EW":1.5,"FTC":1.5},"content_text":"AdvertisementRegulatory shock puts Edwards Lifesciences stock under a sharper lens The Federal Trade Commission’s record $12 million penalty tied to Edwards Lifesciences (EW) acquisition of JC Medical, along with new restrictions on future TAVR AR deals, has pushed the stock’s regulatory risk profile into sharper focus. See our latest analysis for Edwards Lifesciences. Since the FTC action, Edwards Lifesciences’ recent 1 day share price return of 2.4% and 7 day return of 7.03% show selling pressure building, although the 12.08% 1 year total shareholder return points to a stronger longer term picture. If this regulatory setback has you reassessing your healthcare exposure, it could be a good moment to scan other opportunities in medical technology using the 39 healthcare AI stocks Edwards Lifesciences now trades about 12% below one estimate of intrinsic value and roughly 15% below the average analyst target, yet the stock also carries fresh regulatory constraints. Is that discount generous, or just cautious enough? Most Popular Narrative: 13.3% Undervalued Compared with Edwards Lifesciences' last close at $85.73, the most followed narrative points to a fair value of $98.92, supported by detailed revenue, earnings, and margin assumptions under a 7.43% discount rate.  The expected approval of the early TAVR indication in the second quarter, along with policy and guideline changes in the U.S. and globally, represents a multiyear growth opportunity that could significantly enhance revenue streams in the future. The planned launch of the transcatheter tricuspid valve EVOQUE in 2024 is anticipated to uniquely position Edwards to gain market share and increase revenues as it becomes the first company to develop and offer this therapy.  Read the complete narrative. Curious what kind of revenue curve, profit margin lift, and future earnings multiple are baked into that $98.92 figure? The narrative leans on a specific growth path, richer profitability, and a valuation profile that assumes investors will keep paying up for Edwards Lifesciences' structural heart franchise. Result: Fair Value of $98.92 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the story of Edwards Lifesciences can shift quickly if tariff costs weigh more heavily on margins or if competitive pressure in key markets slows TAVR procedure growth. Find out about the key risks to this Edwards Lifesciences narrative. Another view on Edwards Lifesciences valuation The narrative and DCF style estimate suggest Edwards Lifesciences is about 13.3% undervalued, yet the current P/E of 45.9x tells a different story. That is well above the US Medical Equipment industry on 27.5x, peers on 26.1x, and the stock’s own fair ratio of 31.5x. Put simply, Edwards Lifesciences trades on a much richer earnings multiple than both its sector and the P/E level the regression model suggests the market could move toward, which may mean less room for error if earnings or sentiment soften from here. See what the numbers say about this price — find out in our valuation breakdown. NYSE:EW P/E Ratio as at Jul 2026Next Steps If this mix of optimism and concern around Edwards Lifesciences leaves you uncertain, take a closer look at the underlying data now and weigh both sides of the story by reviewing the 2 key rewards and 3 important warning signs Looking for more investment ideas beyond Edwards Lifesciences? Do not stop with Edwards Lifesciences. Broaden your watchlist now with focused stock ideas that could sharpen your portfolio and highlight opportunities you might otherwise miss.  Target income by reviewing companies in the 8 dividend fortresses that may appeal if you want yields backed by stronger fundamentals. Look for potentially mispriced quality by scanning the screener containing 20 high quality undiscovered gems before other investors focus on them. Prioritise resilience by assessing companies in the 84 resilient stocks with low risk scores that may offer smoother performance when markets are volatile.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Edwards Lifesciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2652489232","isCrawlerRequest":true}